Physician profile
Ali A Amini
NPI 1962502997
$5,414.69
in general payments reported to CMS, 2019-2025
23 companies · $720 in 2025
The $720 reported for 2025 was more than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $840 · 2020: $661 · 2021: $470 · 2022: $960 · 2023: $727 · 2024: $1,038 · 2025: $720.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,155 · Gift: $329.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,155.25 |
| Gift | $329.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $2,985.74 | 2019-2025 | Linzess, Rinvoq, Viberzi |
| Braintree Laboratories, INC. | $649.20 | 2019-2024 | Suflave, Sutab |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $544.85 | 2019-2023 | Xifaxan |
| Intercept Pharmaceuticals, INC. | $137.02 | 2019-2024 | Ocaliva |
| Covidien LP | $113.89 | 2019 | |
| Takeda Pharmaceuticals U.S.A., INC. | $112.22 | 2019-2025 | Entyvio |
| Gilead Sciences, INC. | $112.18 | 2023-2025 | |
| Celgene Corporation | $98.05 | 2022 | |
| Genzyme Corporation | $86.23 | 2022-2024 | |
| Celltrion USA INC. | $73.46 | 2025 | Vegzelma |
| Regeneron Healthcare Solutions, INC. | $66.99 | 2022-2025 | Dupixent |
| Fujifilm Healthcare Americas Corporation | $64.59 | 2023 | Fujifilm |
| Nestle Healthcare Nutrition INC. | $64.08 | 2021-2022 | |
| Allergan, INC. | $60.44 | 2019 | |
| Ironwood Pharmaceuticals, INC | $46.36 | 2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Biotech, INC. | $42.95 | 2020-2021 | |
| Pfizer INC. | $36.09 | 2023-2024 | |
| Madrigal Pharmaceuticals | $32.73 | 2024 | Resmetirom |
| Ferring Pharmaceuticals INC. | $26.53 | 2022 | |
| Fresenius Kabi USA, LLC | $22.27 | 2023 | Idacio |
| Olympus America INC. | $15.36 | 2019 | |
| Redhill Biopharma INC. | $12.45 | 2020 | |
| Shire North American Group INC | $11.01 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Amini listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.